Medical Cannabis Hype Hits a Wall as Researchers Reveal Big Evidence Gaps

OG article by University of California - Los Angeles Health Sciences

December 26, 2025

A comprehensive review published in JAMA Psychiatry analyzed over 2,500 studies on medical cannabis from 2010 to 2025, prioritizing 120 high-quality randomized clinical trials, meta-analyses, and guidelines. Researchers found substantial evidence gaps for most claimed benefits, despite widespread public use for conditions like chronic pain, anxiety, and insomnia. A 2018 survey indicated 27% of respondents in the U.S. and Canada used cannabis for these issues.

Strong evidence supports only FDA-approved cannabinoids for specific indications: appetite stimulation in HIV/AIDS, nausea from chemotherapy, and severe epilepsy syndromes in children, such as Dravet and Lennox-Gastaut. For broader applications, including first-line treatment of chronic pain, guidelines advise against use due to insufficient data.

Significant risks were highlighted, including a 29% rate of cannabis use disorder among users. Daily or high-potency consumption increases cardiovascular events like heart attacks and strokes. Adolescent exposure to high-potency products raises risks of psychotic symptoms (12.4% vs. 7.1% for low-potency) and anxiety disorders (19.1% vs. 11.6%).

The authors emphasize the disconnect between public perception and scientific evidence, recommending clinician-led discussions, risk screening, and more rigorous research to address limitations in current studies, including potential biases and confounders.